Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Operating Expenses: 2019-2024

Historic Operating Expenses for Lyell Immunopharma (LYEL) over the last 6 years, with Dec 2024 value amounting to $358.8 million.

  • Lyell Immunopharma's Operating Expenses fell 26.26% to $37.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $342.9 million, marking a year-over-year increase of 57.91%. This contributed to the annual value of $358.8 million for FY2024, which is 45.19% up from last year.
  • According to the latest figures from FY2024, Lyell Immunopharma's Operating Expenses is $358.8 million, which was up 45.19% from $247.1 million recorded in FY2023.
  • Lyell Immunopharma's Operating Expenses' 5-year high stood at $358.8 million during FY2024, with a 5-year trough of $219.7 million in FY2020.
  • In the last 3 years, Lyell Immunopharma's Operating Expenses had a median value of $271.7 million in 2022 and averaged $292.6 million.
  • In the last 5 years, Lyell Immunopharma's Operating Expenses skyrocketed by 113.82% in 2020 and then decreased by 9.05% in 2023.
  • Over the past 5 years, Lyell Immunopharma's Operating Expenses (Yearly) stood at $219.7 million in 2020, then climbed by 2.61% to $225.4 million in 2021, then climbed by 20.55% to $271.7 million in 2022, then declined by 9.05% to $247.1 million in 2023, then surged by 45.19% to $358.8 million in 2024.